My research focus on the identification of KIR2DL2 as a novel immune checkpoint with a modulatory role of CAR- and TCR-T effector function. I have an strong background in molecular genomics and CRISPR/Cas9. My primary fields of study are genetics and immunology. My professional goal focus on either finding a role in industry that allow me to further develop better and safer immunotherapies, or a role in which I can still write and/or correct scientific manuscripts and/or grants.

Author: Fontela, M. G, et al. Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint as a modulator of T-cell effector function. Journal for ImmunoTherapy of Cancer 2022;10. doi: 10.1136/jitc-2022-SITC2022.0225.

Collaborator: Redondo, J., Fontela, M. G et al. ‘Functional characterization of a dual enhancer/promoter regulatory element leading human CD69 expression’. Frontiers in Genetics. October 2020. https://doi.org/10.3389/fgene.2020.552949

Coauthor: Lorente, E., Fontela, M. G et al. ‘Modulation of natural HLA-B*27:05 ligandome by ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 2 (ERAP2)’. Molecular & Cellular Proteomics, 2020, 19 (6) 994-1004. doi:10.1074/mcp.ra120.002014.

Coauthor: A. Márquez and Miguel G. Fontela et al. ‘Fluorescence enhanced BA-LIFT for single cell detection and isolation’. Biofabrication. January 2020. DOI: 10.1088/1758-5090/ab6138.

Author: Miguel G. Fontela et al. ‘The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1’. Genes. August 2019. DOI: 10.3390/genes10090651

Publications in the Molecular Cloud platform (A GenScript platform) are accessible through the following link: https://www.molecularcloud.org/s/miguel-g-mez-fontela